Padcev

Active Ingredient(s): Enfortumab Vedotin-ejfv
FDA Approved: * December 18, 2019
Pharm Company: * ASTELLAS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Padcev Overview

Enfortumab vedotin[1] (AGS-22M6E) is an antibody-drug conjugate[2] designed for the treatment of cancer expressing Nectin-4.[3] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. The most common side effects are fatigue, peripheral neuropathy (nerve damage resulting in tingling or numbness), decreased appetite, rash, alopecia (hair loss), nausea, altered taste, diarrhea, dry eye, prur...

Read more Padcev Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Enfortumab_vedotin

Recent Padcev Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Enfortumab Vedotin-ejfv or a similar ingredient: (1 result)

• ENFORTUMAB VEDOTIN